Cancer Case Against Monsanto For Glyphosate Exposure Sent To Roundup MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Feb. 15 transferred to the multidistrict litigation in the U.S. District Court for the Northern District of California the case of a man who contends that his exposure to glyphosate, the active ingredient in the herbicide Roundup, caused him to develop NK/T-cell lymphoma (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 21, 2017 Category: Medical Law Source Type: news
Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma
Brentuximab vedotin showed clinically superior outcomes compared with standard of care in patients with cutaneous T cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
High-Dose RT Improved Survival in Aggressive Lymphoma
The use of radiotherapy may have an important role in optimizing first-line treatment for patients with early-stage extranodal natural killer/T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 24, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news
Seattle Genetics and Takeda Pharmaceutical complete enrolment for Phase III ECHELON-2 trial of ADCETRIS
Seattle Genetics and Takeda Pharmaceutical have completed patient enrolment for the Phase III ECHELON-2 clinical trial of ADCETRIS (brentuximab vedotin) to treat CD30-positive mature T-cell lymphoma (MTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2016 Category: Pharmaceuticals Source Type: news
Supportive Care for T-Cell Lymphomas
In this interview we discuss the different types of T-cell lymphomas and how supportive care is used in the management of these malignancies. (Source: CancerNetwork)
Source: CancerNetwork - October 1, 2016 Category: Cancer & Oncology Authors: Erin Kopp, ACNP-BC Tags: Hematologic Malignancies Leukemia & Lymphoma Conferences/NCCN 2016 Palliative and Supportive Care Source Type: news
Angimmune ’s Investigational Cutaneous T-cell Lymphoma Disease...
FDA Fast Track Granted to Angimmune(PRWeb September 13, 2016)Read the full story at http://www.prweb.com/releases/angimmune/201609/prweb13679453.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 13, 2016 Category: Pharmaceuticals Source Type: news
Takeda and Seattle Genetics report positive results from Phase III ALCANZA trial of Adcetris to treat CTCL
Takeda Pharmaceutical and Seattle Genetics have reported positive results from the Phase III ALCANZA clinical trial of Adcetris to treat cutaneous T-cell lymphoma (CTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2016 Category: Pharmaceuticals Source Type: news
Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5 times, in a large, longitudinal, population-based cohort study.
Psoriasis also was tied to a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 6, 2016 Category: Dermatology Source Type: news
Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5... (Source: Family Practice News)
Source: Family Practice News - July 6, 2016 Category: Primary Care Source Type: news
PharmaMar begins pivotal study of plitidepsin to treat angioimmunoblastic T-cell lymphoma
Spanish-based biopharmaceutical company PharmaMar has commenced the multicentre, prospective, pivotal study to assess the efficacy of anti-cancer agent plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - June 15, 2016 Category: Pharmaceuticals Source Type: news
PharmaMar announces the start of a pivotal study with plitidepsin in T-cell lymphoma
(Pharmamar) The primary endpoint is to analyze the efficacy of plitidepsin in the type of hematological cancer, angioimmunoblastic T-cell lymphoma, which is classified as a rare disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2016 Category: Cancer & Oncology Source Type: news
Cutaneous T-Cell Lymphoma: Focus on Targeted AgentsCutaneous T-Cell Lymphoma: Focus on Targeted Agents
This review explores the latest targeted therapies which provide treatment options for patients with advanced cutaneous T-cell lymphoma. Which are currently approved and which are under investigation? American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma
Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news
Dose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell LymphomaDose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell Lymphoma
Romidepsin regimens that employ less-frequent dosing can prolong remission in patients with some subtypes of cutaneous T-cell lymphoma (CTCL), according to a retrospective records review. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
APO866 lacks efficacy in cutaneous T-cell lymphoma
The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology. (Source: MedWire News)
Source: MedWire News - April 7, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news
